ArticleJournal of experimental & clinical cancer research : CR2026
Iron diminishes immunosuppressive macrophages and enhances anti-PD-1 immunotherapy in breast cancer models.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundBreast cancer remains a leading cause of cancer-related mortality among women globally, necessitating the development of innovative therapeutic strategies. The efficacy of immune checkpoint inhibitor-based immunotherapy in triple-negative breast cancer has provided a rationale for exploring its expansion to other breast cancer subtypes. Immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment have been demonstrated as a formidable barrier to the efficacy of approved immunotherapy. We aimed to identify and therapeutically modulate pathways that regulate the immunosuppressive properties of TAMs for more effective breast cancer immunotherapies.
methodsWe integrated analyses of publicly available human breast cancer single-cell RNA sequencing (scRNA-seq) datasets with scRNA-seq profiling of murine mammary tumors to identify the signaling pathways associated with immunosuppression. The therapeutic implications of our findings were subsequently assessed through both in vitro and in vivo models. Single-cell transcriptional profiling was further performed to characterize the tumor immune microenvironment and understand the mechanisms of therapeutic activity.
resultsWe revealed a strong positive correlation between iron metabolic gene signature and immunosuppressive features in TAMs of breast cancers. We showed that iron treatment on primary macrophages enhanced the proliferation of activated T cells, which was accompanied by downregulation of immunosuppressive mediators in macrophages. Importantly, we demonstrated that iron supplementation augmented the antitumor effect of PD-1 based immunotherapy in two preclinical models, with increased infiltration and cytotoxic activity of CD8 + T cells. Furthermore, iron treatment functionally reprogramed TAMs toward a less immunosuppressive state, potentially due to the downregulation of NF-κB inflammatory pathways and a shift in cellular metabolism.
conclusionsThese findings advance the pivotal roles of iron in modulating the functional phenotypes of TAMs and anti-tumor immunity, and suggest that iron supplementation may represent a valuable clinical strategy for optimizing anti-PD-1 immunotherapy in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.